Serum endocan and copeptin levels in preterm babies with respiratory distress
Comparative Study Between Endocan and Copeptin Serum Levels in Preterm Neonates With Respiratory Distress Syndrome
Tanta University · NCT07154134
This will test whether blood levels of endocan and copeptin on the first day of life are linked to how severe respiratory distress is in preterm newborns (28–36 weeks).
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 40 (estimated) |
| Ages | 28 Weeks to 36 Weeks |
| Sex | All |
| Sponsor | Tanta University (other) |
| Locations | 1 site (Tanta, El-Gharbia) |
| Trial ID | NCT07154134 on ClinicalTrials.gov |
What this trial studies
This observational study will measure serum endocan and copeptin on day one of life in preterm neonates (28–36 weeks) diagnosed with respiratory distress syndrome. Blood samples will be analyzed for biomarker concentrations and those levels will be correlated with clinical measures of RDS severity. Infants with IUGR, major congenital or chromosomal anomalies, hypoxic ischemic encephalopathy, maternal chorioamnionitis, infants of diabetic mothers, extreme prematurity (<28 weeks), or PROM >2 hours are excluded. The work is single-center at Tanta University and involves no therapeutic interventions beyond routine clinical care.
Who should consider this trial
Good fit: Preterm neonates born at 28–36 weeks gestation with clinical respiratory distress syndrome who do not meet exclusion criteria are eligible.
Not a fit: Infants born before 28 weeks, those with IUGR, major anomalies, chromosomal disorders, hypoxic ischemic encephalopathy, maternal chorioamnionitis, infants of diabetic mothers, or prolonged PROM are excluded and would not benefit from this protocol.
Why it matters
Potential benefit: If successful, these biomarkers could help clinicians identify which preterm babies are likely to have more severe respiratory distress and inform earlier, targeted care.
How similar studies have performed: Previous research has linked endocan and copeptin to inflammation and physiological stress, but their specific use for predicting neonatal RDS severity is limited and not yet widely validated.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Prematurity. * Gestational age between 28 and 36 weeks. * Suffering from respiratory distress syndrome. Exclusion Criteria: * Intrauterine growth restriction (IUGR). * Hypoxic ischemic encephalopathy. * Multiple congenital anomalies. * Chromosomal abnormalities. * Preterm less than 28 weeks. * Neonates with a maternal history of chorioamnionitis (early sepsis). * Infant of diabetic mother. * Prelabor rupture of membranes (PROM)\> 2 hours.
Where this trial is running
Tanta, El-Gharbia
- Tanta University — Tanta, El-Gharbia, Egypt (RECRUITING)
Study contacts
- Study coordinator: Asmaa M Elmesiry, MD
- Email: asmaa.elmesery@med.tanta.edu.eg
- Phone: 00201224285567
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Endocan, Copeptin, Serum, Preterm Neonates, Respiratory Distress Syndrome